OVERVIEW AND OUTLOOK
- Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with Biogen Inc.
- Life Science grows organically by 15.6%, mainly thanks to the Process Solutions business
- Mavenclad and Bavencio drive organic growth of Healthcare; recovery in the Fertility franchise
- Semiconductor Solutions business of Performance Materials grows organically by 8.0%
Outlook for fiscal 2020
- Company expects organic sales growth of 4% to 5% over the previous year and Group net sales of between € 17.1 billion and € 17.5 billion
- Organic growth of EBITDA pre over the previous year excluding provision release between 6% and 8% expected, EBITDA pre in a range between € 5.05 billion and € 5.25 billion
The superb results of the third quarter once again underscore the strength of our diversified business model.
ADDITIONAL INFORMATION
Downloads for the Media
Additional Downloads
- Presentation for Analysts (PDF)
- Financial Statement (XLS)
- Financial Statement (PDF)
- Regional Sector Sales (XLS)
- Summary (PDF)
Annual Reports Archive
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
Quarterly Statement
Q3 2020
Merck KGaA, Darmstadt, Germany grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany, Reports Strong Third Quarter
Merck KGaA, Darmstadt, Germany, grew significantly in the third quarter. In comparison with the year-earlier quarter, Group net sales increased by 9.7% to € 4.4 billion.
2020/11/12
Upcoming Event
View All EventsOur Q2 2021 results will be published on August 5, 2021, at 7 a.m. CEST. Our conference call for the media will take place at 9:30 a.m. CEST, and the conference call for analysts at 2 p.m. CEST.
Share Price
Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.
Check Share Price